{
    "organizations": [],
    "uuid": "253704e3de3a4b02110a2d074fcfeb56838807e2",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-sage-therapeutics-receives-fda-bre/brief-sage-therapeutics-receives-fda-breakthrough-therapy-designation-for-sage-217-idUSASB0C4EY",
    "ord_in_thread": 0,
    "title": "BRIEF-Sage Therapeutics Receives FDA Breakthrough Therapy Designation For Sage-217",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 7 (Reuters) - Sage Therapeutics Inc:\n* SAGE THERAPEUTICS RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR SAGE-217 FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER\n* SAGE THERAPEUTICS INC - SAGE-217 WAS GENERALLY WELL-TOLERATED\n* SAGE THERAPEUTICS INC - IN TRIAL, SAGE-217 MET PRIMARY ENDPOINT Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-07T19:39:00.000+02:00",
    "crawled": "2018-02-07T13:46:57.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "sage",
        "therapeutic",
        "inc",
        "sage",
        "therapeutic",
        "receives",
        "fda",
        "breakthrough",
        "therapy",
        "designation",
        "treatment",
        "major",
        "depressive",
        "disorder",
        "sage",
        "therapeutic",
        "inc",
        "generally",
        "sage",
        "therapeutic",
        "inc",
        "trial",
        "met",
        "primary",
        "endpoint",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}